According to a new report by Polaris Market Research, the U.S. DNA Manufacturing market was valued at USD 2.22 billion in 2024 and is projected to reach USD 11.72 billion by 2034, expanding at a CAGR of 18.14% over the forecast period. Growth is underpinned by the rising prevalence of rare diseases, expanding demand for personalized medicine, and increasing healthcare spending driving investment in gene therapy and mRNA vaccine manufacturing.

What Is Driving U.S. DNA Manufacturing Market Growth?

Demand is climbing as rising rare-disease diagnoses converge with expanding personalized medicine development. Biopharmaceutical companies are prioritizing high-quality plasmid and synthetic DNA, pushing DNA manufacturing adoption across gene therapy, vaccine, and oligonucleotide drug development. Polaris analysts note that the FDA reports over 7,000 rare diseases affecting more than 30 million Americans, positioning the market for sustained growth through 2034, with plasmid DNA emerging as the largest revenue contributor and contract research organizations posting the fastest incremental gains.

Key Trends Shaping the U.S. DNA Manufacturing Industry

GMP-Grade Scale-Up for Advanced Biologics

Rising clinical trial activity for CRISPR-based treatments, CAR-T cell therapies, and mRNA vaccines is driving technology advancement toward GMP-grade DNA production that meets FDA and EMA compliance requirements.

Rising Healthcare Spending on Genomic Medicine

U.S. health spending reached $4.9 trillion in 2023, per the American Medical Association, reshaping the investment landscape as hospitals and biotech firms channel funding into next-generation sequencing and gene therapy infrastructure.

Faster Regulatory Pathways for Gene Therapies

Streamlined FDA approval pathways are reshaping the regulatory landscape, giving manufacturers confidence to invest in large-scale plasmid and synthetic DNA production capacity.

Market Segmentation: Breaking Down the U.S. DNA Manufacturing Market

Polaris segments the U.S. DNA manufacturing market by type, grade, application, and end use, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Type

The plasmid DNA segment accounted for a major market share in 2024, driven by its critical role in cell and gene therapies, DNA vaccines, and viral vector production requiring GMP-grade quality for clinical use.

By Grade

The GMP grade segment held a larger market share in 2024, reflecting rising clinical trial activity for advanced biologics and stringent FDA and EMA compliance requirements.

By Application

The cell & gene therapy segment dominated the market in 2024, fueled by advancements in CRISPR-based gene editing and CAR-T cell therapies, while regulatory approvals for sickle cell disease treatments further reinforced demand.

Explore The Complete Comprehensive Report Here:

https://www.polarismarketresearch.com/industry-analysis/us-dna-manufacturing-market 

Regional Outlook: Where Is U.S. DNA Manufacturing Growing Fastest?

The market's growth is concentrated across the United States, where biopharmaceutical hubs are scaling plasmid and synthetic DNA production to meet rising clinical and commercial demand. Contract research organizations are expanding rapidly as pharmaceutical companies increasingly outsource DNA manufacturing for preclinical and early-stage research, leveraging specialized expertise in synthetic biology and genomics to reduce costs and accelerate development timelines.

Competitive Landscape: Leading U.S. DNA Manufacturing Companies

Key players profiled in the report include Thermo Fisher Scientific, Twist Bioscience, GenScript, and Lonza, who are focusing on advanced oligonucleotide synthesis platforms and GMP-grade capacity expansion to strengthen market position across the plasmid DNA and cell & gene therapy segments outlined above. Recent moves include Aldevron's May 2025 manufacture of a personalized CRISPR gene editing drug product for an infant with urea cycle disorder and Bionova Scientific's June 2024 launch of a dedicated plasmid DNA facility in Texas, both aimed at deepening share in gene therapy manufacturing.

Why It Matters for Buyers Evaluating Gene Therapy Supply Chains

For stakeholders researching U.S. DNA manufacturing market share, this report benchmarks segment-level pricing and forecast data — by type, grade, application, and end use — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing suppliers, investors sizing entry points, and strategy teams tracking contract research organizations as a growth adjacency.

About Polaris Market Research

Polaris Market Research is a B2B syndicated market research and consulting firm offering 5,000+ published reports across 20+ industry verticals, delivering data-backed insights to help businesses make informed decisions.

More Trending Latest Reports By Polaris Market Research:

PET-CT Scanner Device Market

Glioblastoma Multiforme (GBM) Treatment Market

Black Beer Market

Surgical Suction Instruments Market

Semantic Knowledge Graphing Market

Semantic Knowledge Graphing Market

Botulinum Toxin Market

Passenger Drones Market

Smokeless Tobacco Products Market